Company / R&D per Share
Sarepta Therapeutics R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$15.71
FY2025
5-year range
$8.29 / $15.71
FY2021-FY2025
Trend
+83.0%
vs FY2024
Sector context
#7 of 208
Health Care
What the data says
Among 208 Health Care companies, Sarepta Therapeutics is in the top 3% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.71 in FY2018 to $15.71 in FY2025.
Based on SEC 10-K filings.
15.71 in FY2025 with a 5-year CAGR of +24.1%. Top quartile in the Health Care sector.
Improved from $9.98 to $15.71 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +23.7%
- 5-Year CAGR
- +24.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 208This company $15.71 Sector average $28.82
▼
-45.5% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 83.0% year-over-year.
- Ranks #7 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.71 | +83.0% |
| FY2024 | $8.58 | -14.0% |
| FY2023 | $9.98 | +20.3% |
| FY2022 | $8.29 | -14.7% |
| FY2021 | $9.72 | +81.8% |
| FY2020 | $5.34 | +319.5% |
| FY2019 | $1.27 | +78.7% |
| FY2018 | $0.71 | -76.6% |
| FY2017 | $3.04 | -26.2% |
| FY2016 | $4.13 | +19.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026